Mont-Saint-Guibert, Belgium, November 30, 2023, 10.01 pm CET – regulated information – Celyad Oncology SA (Euronext: CYAD) (“Celyad Oncology” or the “Company”) today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the “Transparency Law”), that it received a transparency notification dated November 28, 2023, from Tolefi SA and related persons indicating that they have jointly crossed passively below the 15% threshold, holding 6,568,978 voting rights, or 14.997 % of the voting rights of the Company as of November 14, 2023.
Content of the Notification:
- Reason of the Notification:
- Threshold crossing passively
- Notification by:
- Persons acting in concert
- Persons subject to the notification requirement:
- Tolefi SA, Chaussée de Waterloo 1589D, 1180 Uccle
- Serge Goblet
- Isabelle Thoumyre
- Jérôme Goblet
- Jean-Daniel Goblet
- Date on which the threshold is crossed:
- November 14, 2023
- Threshold that is crossed (in %):
- 15
- Denominator:
- 43,796,947
- Notified details:
| A) Voting Rights | Previous notification | After the Transaction | |||
| #of voting rights | # of voting rights | % of voting rights | |||
| Holders of voting rights | Linked to the securities | Not linked to the securities | Linked to the securities | Not linked to the securities | |
| Tolefi SA | 6,504,854 | 6,504,864 | 0 | 14.85% | 0.00% |
| Serge Goblet | 56,180 | 56,180 | 0 | 0.13% | 0.00% |
| Isabelle Thoumyre | 7,300 | 7,300 | 0 | 0.02% | 0.00% |
| Subtotal | 6,568,344 | 6,568,344 | 15% | ||
| Jérôme Goblet | 250 | 250 | 0 | 0,00% | 0.00% |
| Jean-Daniel Goblet | 384 | 384 | 0 | 0,00% | 0.00% |
| TOTAL | 6,568,978 | 0 | 15% | 0.00% | |
| TOTAL (A & B) | # of voting rights | % of voting rights |
| 6.568.978 | 15.00 % |
- Full chain of controlled undertakings through which the holdings is effectively held:
- Tolefi SA is 100% owned by Serge GOBLET, Mrs THOUMYRE and their children.
- Additional Information:
- Due to rounding of the form, the percentage shown is 15%, but the actual percentage is 14.997%.
Miscellaneous
- The Press Release may be consulted on the website of Celyad Oncology: https://celyad.com/newsroom/
- The notification can be consulted on the website of Celyad Oncology https://celyad.com/investors/regulated-information/
- Contact person(s): Any transparency notification must be sent to our Company by email to the attention of Georges Rawadi, Chief Executive Officer (CEO): investors@celyad.com
